Evaluating CART-EGFR-IL13Ra2 Cells Following Lymphodepleting Chemotherapy in Patients With EGFR-Amplified Recurrent Glioblastoma
Brief description of study
This research study is being conducted to evaluate an experimental drug called CART EGFR-IL13Ra2 cells in patients with glioblastoma that has returned or worsened on current treatment.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Lymphodepleting Chemotherapy,Glioblastoma
-
Age: - 99 Years
-
Gender: All
Updated on
09 Mar 2024.
Study ID: 850297
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
